OrganiGram (OGI)
(Delayed Data from NSDQ)
$1.78 USD
+0.04 (2.30%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.78 USD
+0.04 (2.30%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Zacks News
Are Medical Stocks Lagging OrganiGram (OGI) This Year?
by Zacks Equity Research
Here is how OrganiGram (OGI) and ResMed (RMD) have performed compared to their sector so far this year.
Why OrganiGram (OGI) Might Surprise This Earnings Season
by Zacks Equity Research
OrganiGram (OGI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Rockwell Medical (RMTI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 41.67% and 0.43%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Organigram (OGI) Grows in Cannabis Space With SHRED X Heavies
by Zacks Equity Research
Organigram's (OGI) SHRED X Heavies is not only the first infused pre-roll in the SHRED product portfolio but also joins a lineup of value-driven, convenient and bold-flavored offerings.
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -91.67% and 10.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in SurModics (SRDX): Can Its 16.1% Jump Turn into More Strength?
by Zacks Equity Research
SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Stryker (SYK) Moves 4.2% Higher: Will This Strength Last?
by Zacks Equity Research
Stryker (SYK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
High Tide Inc. (HITI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
High Tide Inc. (HITI) delivered earnings and revenue surprises of 75% and 2.70%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of -100% and 9.74%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
OraSure (OSUR) Stock Jumps 9.3%: Will It Continue to Soar?
by Zacks Equity Research
OraSure (OSUR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
OrganiGram (OGI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 1.43%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
OrganiGram (OGI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
OrganiGram (OGI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akerna Corp. (KERN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akerna Corp. (KERN) delivered earnings and revenue surprises of -13.33% and 4.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ThermoGenesis Holdings, Inc. (THMO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -233.33% and 28.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Veru Inc. (VERU): Can Its 39.5% Jump Turn into More Strength?
by Zacks Equity Research
Veru Inc. (VERU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Envista (NVST) Q3 Earnings Match Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 0% and 0.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OrganiGram (OGI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of -50% and 5.67%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
High Tide Inc. (HITI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
High Tide Inc. (HITI) delivered earnings and revenue surprises of -175% and 3.49%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
OrganiGram (OGI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.15%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
Will OrganiGram (OGI) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
OrganiGram (OGI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neogen (NEOG) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -13.33% and 1.35%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
Akerna Corp. (KERN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akerna Corp. (KERN) delivered earnings and revenue surprises of -14.29% and 22.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OrganiGram (OGI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.44%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
Will OrganiGram (OGI) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
OrganiGram (OGI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OrganiGram (OGI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of -75% and 3.22%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?